We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher to Acquire Life Technologies for USD 13.6 Billion

By LabMedica International staff writers
Posted on 22 Apr 2013
Print article
Thermo Fisher Scientific (Waltham, MA, USA) and Life Technologies Corporation (Carlsbad, CA, USA) have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies, creating enhanced capabilities for serving life science research, specialty diagnostics, and applied markets. The acquisition will take place for approximately USD 13.6 billion (plus the assumption of net debt at close—USD 2.2 billion as of yearend 2012).

The transaction will create a superior industry leader by building on both companies’ strengths for life sciences, such as proteomics, genomics, and cell biology. It will also strengthen technology and innovation leadership through complementary offerings that further broaden Thermo Fisher’s portfolio. Life Technologies provides innovative services and products (about 5,000 patents and licenses), offering a broad range of reagents, consumables, instruments, and systems. Life has an extensive offering of consumables for genomics, and molecular and cell biology and a range of technologies for bioproduction and forensics; it is also well known for its next-generation sequencing capability. These strengths, combined with Thermo Fisher’s leading offerings in analytical technologies and specialty diagnostics, create new convergence opportunities. The acquisition also enhances Thermo Fisher’s global reach. Life transacts more than half of its orders online through a highly regarded e-commerce platform. This leading capability, combined with Thermo Fisher’s extensive customer channels, creates a world-class infrastructure.


“This transaction enhances [...] our growth strategy: technological innovation, a unique customer value proposition, and expansion in emerging markets,” said Marc N. Casper, president and CEO of Thermo Fisher Scientific. Gregory T. Lucier, chairman and CEO of Life Technologies, said, “We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees, and the communities we serve.” Mr. Casper added, “Together we will be in an even stronger position to fulfill our company’s mission, which is to enable our customers to make the world healthier, cleaner, and safer.”

Related Links:

Thermo Fisher Scientific
Life Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Researchers have found a way to spot the debilitating disease Alzheimer\'s before it develops into dementia (Photo courtesy of 123RF)

Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia

Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more